BRISBANE, Calif., July 7, 2011 /PRNewswire/ -- InterMune (NASDAQ: ITMN) today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from ...

During the American Thoracic Society’s Annual Meeting in Dallas, Texas, taking place May 17-22, 2019, researchers will present findings from a study investigating pirfenidone (Esbriet ...